REDWOOD CITY, Calif.–(BUSINESS WIRE)–Dec. 30, 2024– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and…Original Article
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
